aTyr Pharma, Inc. (ATYR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.29. The rating moved from Strong Oversold to Oversold on October 2, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$0.29
• Last changeMoved from Strong Oversold to Oversold on October 2, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

aTyr Pharma, Inc. (ATYR) is a small-cap, early-stage biotech with limited late-stage clinical validation and a thin balance sheet. The company faces near-term financing and dilution risk, high outcome sensitivity to clinical data, and low liquidity that amplifies downside in a risk-off market. Monitor cash runway, upcoming data readouts, partnership activity, and any financing announcements as the primary events that will determine short-term direction.

Key factors

• Early-stage development profile with limited late-stage clinical validation and no recent material positive pivotal readouts
• Constrained balance sheet and likely need for near-term financing, raising dilution risk for existing shareholders
• Risk-off market environment reducing demand for speculative biotech and small-cap healthcare names
• Low liquidity and small float, which amplifies share-price volatility on both downside news and micro-cap trading flows
• Sector tailwinds for rare-disease and late-stage biologics are selective and do not clearly de-risk aTyr’s specific pipeline
• Potential upside exists from partnerships, licensing deals, or positive early clinical signals, which would be required to materially re-rate the stock

Risks

• Clinical trial failures or disappointing safety/efficacy results that materially reduce asset value
• Near-term equity or convertible financing that dilutes current shareholders and depresses the share price
• Regulatory and payer pressure on pricing (including Medicare negotiation dynamics) that could limit future commercial value
• Continued market-wide risk aversion and reduced IPO/venture liquidity that constrains strategic options
• Competitive advances from larger biotech/pharma in adjacent therapeutic areas that could limit partnership interest
• Low trading volume and market microstructure risk that could produce sharp intraday moves independent of fundamentals

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.